Hamada Kosuke, Fujiwara Ryo, Takemura Kosuke, Komai Yoshinobu, Oguchi Tomohiko, Numao Noboru, Yamamoto Shinya, Yonese Junji, Yuasa Takeshi
Department of Genitourinary Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Int J Urol. 2022 Oct;29(10):1181-1187. doi: 10.1111/iju.14964. Epub 2022 Jun 18.
To investigate the tumor shrinkage patterns of patients with metastatic renal cell carcinoma treated with nivolumab monotherapy.
Forty-four consecutive patients with metastatic renal cell carcinoma treated with nivolumab monotherapy (81 metastatic and four primary lesions) between September 2013 and December 2020 were retrospectively analyzed. The tumor shrinkage rate of individual visceral and lymph node metastatic lesions and the primary site lesions treated with nivolumab monotherapy, as well as the association between overall survival and pretreatment tumor size, were statistically assessed.
Pretreatment tumor size for the total and individual target lesions, which included kidneys, lungs, pancreas, and lymph nodes, were not correlated with tumor shrinkage rate. The tumor shrinkage rate was found to have no significant association with pretreatment tumor size between any organ. In addition, there is no significant difference in tumor shrinkage rate between larger (>median value) and smaller (<median value) pretreatment tumor size in any organ. Finally, there was no significant difference in overall survival between larger and smaller pretreatment tumor size.
Pretreatment tumor size was not associated with the tumor shrinkage rate and overall survival in nivolumab monotherapy.
研究接受纳武利尤单抗单药治疗的转移性肾细胞癌患者的肿瘤缩小模式。
回顾性分析了2013年9月至2020年12月期间连续接受纳武利尤单抗单药治疗的44例转移性肾细胞癌患者（81个转移灶和4个原发灶）。对接受纳武利尤单抗单药治疗的各个内脏和淋巴结转移灶以及原发部位病灶的肿瘤缩小率，以及总生存期与治疗前肿瘤大小之间的关联进行了统计学评估。
包括肾脏、肺、胰腺和淋巴结在内的总体及各个靶病灶的治疗前肿瘤大小与肿瘤缩小率均无相关性。发现肿瘤缩小率与任何器官之间的治疗前肿瘤大小均无显著关联。此外，在任何器官中，治疗前肿瘤大小较大（>中位数）和较小（<中位数）的肿瘤缩小率均无显著差异。最后，治疗前肿瘤大小较大和较小的患者总生存期无显著差异。
在纳武利尤单抗单药治疗中，治疗前肿瘤大小与肿瘤缩小率及总生存期无关。
